The other day, I noted a www.Ilcellulartherapy.com (my web site) request from a patient seeking to schedule an appointment at my office. That phone call had been placed ten days earlier and my assistants failed to respond in a timely manner. When eventually returned, the potential patient indicated that she had decided to seek consultation elsewhere. I can understand her frustration and yet would her orthopedic needs have been better served by placing a second request?  I share this with you and admit we are human; as hard as we try in achieving 100% patient satisfaction, at times the system doesn’t operate as intended. The ultimate question is where to seek Cellular Orthopedic consultation and treatment even if initially, the response is not as either side would like?

For almost five years of a Cellular Orthopedic, Regenerative Medicine practice, I have integrated patient care with clinical research. This is my contribution to the evolving discipline of Stem Cell therapy for arthritis; and is based on what I introduced into orthopedic surgery during my 37-year academic joint replacement career. It is only by monitoring outcomes that we continue to learn and improve results.

Listed below are my clinical research endeavors over the past five years and the basis for my clinical recommendations:

1) Stem Cell Counts and the Outcome of Bone Marrow Concentrate intra-articular and intra-osseous (subchondroplasty) interventions at the knee for grades 2 and 3 OA. (supported in part by Celling). Ongoing

2) Outcomes of Bone Marrow Concentrate (stem cell, platelet and growth factor) Intervention at the Knee for Grades 2 and 3 OA in 50 patients at 2 to 4 years. (supported in part by Regenexx)

3) Outcomes of Intra-articular Bone Marrow Concentrate versus those of combined Intraarticular and Intraosseous interventions for grades 2 and 3 OA at the knee at one year. (self-funded). Ongoing

4) How does the PRP and Mononucleated cell count affect the outcome of a BMC intervention for grades 2 and 3 Knee OA? (a joint project with Greyledge) Ongoing

5) Safety and Efficacy of Percutaneous Injection of Micro-Fractured Adipose Tissue for grade 4 Osteoarthritic Knees, minimum follow-up of 18 months in 30 patients (supported in part by Lipogems)

6) A Lyophilized Amniotic Fluid Clinical Trial for Grades 2 and 3 Knee OA (supported by MiMedx) Ongoing

7) An Amniotic Fluid Cryopreserved Clinical Trial for Grades 2 and 3 Knee OA in 30 patients. (supported by MiMedx)

8) An Amniotic Fluid Cryopreserved Clinical Trial for Grades 2 and 3 Knee OA in 45 patients. (sponsored by Liventa)

We Have The Evidences for Cellular Orthopedics; ask the camp followers to show you theirs.

To schedule an office visit call 312 475 1893   and please be patient.